Dr Amaria discusses her ASCO21 highlights for melanoma, including results from the neoadjuvant and adjuvant nivolumab data with anti-LAG3 antibody relatlimab for patients with with clinical stage III or oligometastatic stage IV melanoma (abstract 9502), results from the RELATIVITY-047 study –the first randomized phase III trial to evaluate the IO agents anti–PD-1 therapy nivolumab plus relatlimab – a LAG-3-blocking antibody-in patients with untreated, unresectable or metastatic melanoma (abstract 9503). She also provides her clinical insights about the updated findings from the LEAP-004 phase II study evaluating lenvatinib plus pembrolizumab in advanced melanoma following prior PD-(L)1 therapy (abstract 9504) and the phase II efficacy and safety study of lifileucel adoptive T-cell therapy in patients with advanced melanoma (abstract 9505).

Dr Parikh discusses her ASCO21 highlights for gastrointestinal cancer, including results from the pivotal KEYNOTE-177 study of pembrolizumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC) (abstract 3500) and the results from DESTINY-CRC01, the phase II trial evaluating trastuzumab derustecan in patients with HER2-expressing advanced colorectal cancer (abstract 3505). She also discusses the CHRONOS trial- a phase II study of anti-EGFR rechallenge therapy with panitumumab in mCRC (abstract 3506).

Dr Chau takes us through his ASCO21 highlights in upper tract gastrointestinal cancer, including the ESCORT-1st (abstract 4000), CheckMate 648 (abstract LBA4001), and CheckMate 649 (abstract 4002) trials in the advanced setting, and the Neo-AEGIS (abstract 4004) and CheckMate 577 (abstract 4003) trials in patients with localized disease.

Dr Goto shares discusses the safety and efficacy findings of the phase 1 clinical trial of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody-drug conjugate, in patients with advanced EGFR-mutant NSCLC (abstract 9007). He also highlights the results from the phase 3 IMPACT trial of adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with phase 2-3 EGFR-mutated NSCLC (abstract 8501).

Dr Bardia tells us about his early and metastatic breast cancer highlights from ASCO21, including the OlympiA (LBA1), ECOG-ACRIN EA1131 (abstract 605), GeparNUEVO (abstract 506), and VERONICA (abstract 1004) trials, as well as a patient advocate-led survey seeking to understand the views of metastatic breast cancer patients on drug dosing (abstract 1005).

Professor Craddock discusses three hematology-oncology abstracts from the ASCO21 Annual Meeting reporting on the use of letermovir to prevent cytomegalovirus reactions in allogeneic stem cell transplant recipients with graft versus host disease (abstract 7004), first-line asparcytarabine in acute myeloid leukemia patients unfit for standard chemotherapy, and the initial results from the V-FAST trial of CPX-351 plus targeted agents for newly diagnosed acute myeloid leukemia.